Sirolimus for Recurrent Giant Cell Myocarditis After Heart Transplantation: A Unique Therapeutic Strategy

Area of Science:

• Cardiology
• Immunology
• Transplantation

Background:

• Giant cell myocarditis (GCM) is a rare, aggressive cardiac condition often necessitating heart transplantation.
• Recurrence of GCM post-transplantation presents a significant therapeutic challenge.

Observation:

• A patient with a history of Crohn disease experienced recurrent GCM despite aggressive immunosuppression following orthotopic heart transplantation.
• Standard immunosuppressive regimens, including corticosteroids, basiliximab, tacrolimus, antithymocyte globulin, and rituximab, were insufficient to control GCM recurrence.

Findings:

• Sirolimus, an inhibitor of T- and B-lymphocyte proliferation, was added to the existing immunosuppressive regimen.
• Following the initiation of sirolimus, the patient remained disease-free, indicating successful management of GCM recurrence.

Implications:

• Sirolimus represents a promising therapeutic option for managing recurrent giant cell myocarditis after heart transplantation.
• This case highlights the potential of targeted immunosuppression in addressing refractory post-transplant GCM, particularly in patients with complex medical histories.